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Are Elevated Vancomycin Serum Trough Concentrations Achieved Within the First 7 Days 
of Therapy Associated With Acute Kidney Injury in Children? 
 
Chad A. Knoderer, Kristen R. Nichols, Kelsey C. Lyon, Megan M. Veverka, and Amy C.Wilson 
Background. In 2008, the empiric vancomycin dosing recommendation in children at our institution was 
changed from 40 to 60 mg/kg per day. Subsequently, an increased incidence of acute kidney injury (AKI) in 
patients receiving vancomycin was suspected. The objective of this study was to evaluate AKI in children 
receiving vancomycin and to determine risk factors for AKI development. 
Methods. Medical records of patients aged 30 days through 17 years who received vancomycin for at 
least 72 hours between January and December 2007 (40 mg/kg per day) and January and December 2010 
(60 mg/kg per day) were reviewed. Patients with cystic fibrosis, an elevated baseline serum creatinine, or 
without a serum creatinine concentration obtained after receipt of vancomycin were excluded. Acute kidney 
injury was defined using adapted pediatric RIFLE criteria as an increase in serum creatinine from baseline of 
50% or more. 
Results. Acute kidney injury occurred in 19.4%of the 859 children included, with no difference between the 
2007 and 2010 periods (18.8% vs 20%, respectively; P = .636). Intensive care unit admission (odds ratio [OR], 
1.86; 95% confidence interval [CI], 1.20–2.94) and an initial vancomycin trough concentration ≥15 mg/L 
(OR, 2.18; 95% CI, 1.21–3.92) were determined to be significantly associated with AKI. 
Conclusions. These results suggest an initial vancomycin serum trough concentration of ≥15 mg/L and 
intensive care unit admission are predictors of AKI in this pediatric population. 
BACKGROUND 
Vancomycin is commonly used in the pediatric population for empiric or targeted treatment of 
methicillin-resistant Staphylococcus aureus (MRSA) infections and has been associated with 
acute kidney injury (AKI) [1].Empiric intravenous (IV) vancomycin in children has traditionally 
been dosed as 40 mg/kg per day in 4 divided doses to achieve target serum trough concentrations 
of 5–10 mg/L. Recent evidence and recommendations suggest that such doses are unlikely to 
achieve the goal serum trough concentrations (10–20 mg/L) that are necessary for the optimal 
area under the curve (AUC) for plasma concentration relative to the organism minimum 
inhibitory concentration (MIC) (AUC/MIC) [2-5]. 
 
In 2008, the recommendation for empiric vancomycin dosing in children at our institution was 
changed from 40 to 60 mg/kg per day. Subsequently, an increased AKI incidence in patients 
receiving vancomycin was suspected. The observed increase was anecdotally attributed to higher 
vancomycin doses, with acknowledgment that it could be related to other factors. 
 
Adult patients experiencing initial vancomycin serum trough concentrations ≥15 mg/L have a 
higher incidence of nephrotoxicity, and they may be at higher risk for AKI development [6-10]. 
Pediatric data are limited to a small series of patients reported by McKamy et al [11], in which 
children with a mean vancomycin serum trough concentration (throughout the course of therapy) 
of 15 mg/L or greater were at higher risk for developing nephrotoxicity. There are currently no 
additional published pediatric data available. The objectives of this study were to evaluate AKI 
in children receiving vancomycin and to determine factors associated with AKI development. 
 
 
 
 
MATERIALS AND METHODS 
 
Study Design and Population 
 
This was a retrospective, single-center cohort study. Hospital clinical decision support and 
pharmacy data were used to identify patients aged 30 days through 17 years who received 
vancomycin for at least 72 hours during the calendar years 2007 and 2010. The selected time 
frames represent periods before and after the recommended dosing change. Although the 
pharmacy-recommended dosewas increased, prescribers retained the responsibility for individual 
vancomycin dosing decisions. 
 
Patients were excluded if they had baseline (before initial vancomycin dose) serum creatinine 
concentrations (SCr) above institutional age-adjusted normal values, no SCr obtained following 
vancomycin initiation, or cystic fibrosis. Patients receiving multiple vancomycin courses during 
the same hospitalization had only data from the first vancomycin course included. 
Medical records were reviewed to extract baseline demographic and clinical data, vancomycin 
dosing information, and history of exposure to other factors known to be associated with higher 
risk of AKI (ie, intensive care unit [ICU] admission, extracorporeal membrane oxygenation 
utilization, sepsis). Sepsis was determined by using medical coding information captured by the 
hospital’s information management system. Concurrent nephrotoxins (aminoglycosides, 
tacrolimus, meropenem, cyclosporine, scheduled nonsteroidal anti-inflammatory drugs, IV 
acyclovir, amphotericin B deoxycholate, IV contrast dye) were also assessed. Serum creatinine 
concentrations were collected from before vancomycin initiation and for 7 days after. Patients’ 
initial vancomycin trough serum concentrations were also collected and categorized as described 
above (≥15 mg/L), or within or below (<15 mg/L) target range. 
 
Outcomes 
 
Acute kidney injury was defined as an increase in serum creatinine by ≥50% from baseline, as 
adapted from pediatric RIFLE (pRIFLE) criteria [12]. The primary outcome analyzed was AKI 
incidence as determined by pRIFLE criteria. Secondary outcomes included need for renal 
replacement therapy (RRT), determined by ICD-9 coding for RRT (39.95 and 54.98), and in-
hospital mortality. 
 
Data Analysis 
 
Baseline demographics and clinical characteristics were compared using independent samples t 
tests, χ2 analyses, and Mann-Whitney tests for nonparametric data. Logistic regression analysis 
of pRIFLE AKI was utilized using a forced entry method. Variables were included in the final 
regression model if they had a P value <.25 after univariate analysis. P values less than .05 were 
considered to be statistically significant. Statistical analyses were conducted using Statistical 
Package for Social Sciences version 19.0 (SPSS, Inc, Chicago, IL). The study was approved by 
the Indiana University institutional review board. 
 
 
 
RESULTS 
 
Hospital and pharmacy records initially identified 1480 patient-courses eligible for study 
inclusion. After exclusions, a total of 859 patients were included in the final analysis. Baseline 
demographics (gender, age, weight) of patients in the 2007 and 2010 treatment groups were 
similar. The mean empiric vancomycin dose received was increased in 2010 (43.2 ± 16.6 mg/kg 
per day) vs 2007 (40.1 ± 14.6 mg/kg per day); P = <.05. The percentage of patients who received 
a ≥60 mg/kg per day empiric vancomycin dose also increased (31.5% vs 18.3%; P < .05). The 
median (interquartile range [IQR]) initial vancomycin serum trough concentration (mg/L) was 
higher in 2010 than in 2007 (8.9 [6.1–12.6] vs 7.7 [5.6–10.8], respectively; P < .05). Although 
the mg/kg per day dosing difference is not clinically significant, more patients in 2010 (15%) 
achieved an empiric trough concentration of ≥15 mg/L compared to those in 2007 (8%; P < .05). 
Acute kidney injury determined by pRIFLE criteria occurred in 19.4% (167 of 859) of all 
patients. There was no difference in AKI 
rate between the 2007 (76 of 405; 18.8%) and 2010 (91 of 454; 20%) groups (P = .636). 
 
Table 1 summarizes characteristics of patients with and without AKI. The mean ± standard 
deviation empiric vancomycin dose (mg/kg per day) was similar in patients with and without 
AKI (43.1 ± 15.7 vs 41.6 ± 15.6, respectively; P = .294). Acute kidney injury occurred more 
frequently in children achieving an initial vancomycin trough concentration of  >15 mg/L (33.3% 
vs 18.6%; P = <.05). There were no differences in rates of exposure to concomitant nephrotoxic 
medications between patients with and  without AKI except for meropenem (21% vs 13.3%; P = 
<.05). As expected, ICU (neonatal or pediatric) admission occurred significantly more frequently 
in patients with AKI (57.5% vs 40.8%; P < .05), but no other differences in nephrotoxic factors 
were observed (Table 1). In multivariate logistic regression analysis, ICU admission (odds ratio 
[OR], 1.86; 95% confidence interval [CI], 1.20–2.94) and an initial vancomycin trough 
concentration 
of ≥ 15 mg/L (OR, 2.18; 95% CI, 1.21–3.92) were found to be independently associated with 
AKI development. 
 
Among patients with AKI, serum creatinine increased 50%–877% above baseline, with a 75% 
(60%–120%) median (IQR) increase. Magnitude of increase in creatinine was similar between 
AKI patients with and without an initial vancomycin trough concentration of ≥15 mg/L (median 
[IQR] 95 [65.5–136.5] and 68 [55–106], respectively; P = .077). Renal replacement therapy need 
was unchanged in patients with initial vancomycin trough concentrations of ≥15 mg/L, although 
absolute numbers of patients requiring RRT were low (3.2% and 0.6%, respectively; P = .103). 
All-cause mortality was increased in patients with AKI (9% vs 2.7%; OR, 3.5; 95% CI, 1.7–7) 
and also in patients with an initial vancomycin trough concentration of ≥15 mg/L (9% vs 2.7%; 
OR, 3.4; 95% CI, 1.1–10). 
 
 
 
 
 
 
 DISCUSSION 
The need for increased empiric vancomycin doses relates directly to the drug’s 
pharmacokinetic/pharmacodynamics (PK/PD) parameters and increasing MRSA resistance 
incidence [3]. Clinical efficacy with vancomycin is most likely optimized in adult patients when 
an AUC/MIC ratio of at least 400:1 is attained. The vancomycin serum trough concentration is 
an appropriate surrogate, and values of 15–20 mg/L in adult patients correlate with AUC/MIC of 
at least 400:1 for MRSA isolates with MIC values of ≥ 1 mg/L to vancomycin [3]. Recent 
pediatric data suggest that AUC/MIC of 400:1 correspond with vancomycin trough 
concentrations of 7–10 mg/L. Targeting a trough concentration of 15–20 mg/L in children may 
actually lead to vancomycin overexposure and increase the potential for toxicity [13, 14]. 
Decreasing susceptibility of MRSA to vancomycin in the adult population has resulted in the 
utilization of increased empiric vancomycin doses to target initial trough concentrations of 15–20 
mg/L. Although there is limited but similar data in children, it is important to evaluate recent 
pediatric PK/PD data along with bacterial resistance trends when considering dosing strategy 
changes. 
 
Vancomycin has long been considered nephrotoxic, but more recent literature has firmly 
established an association 
between vancomycin exposure and kidney injury. Adult patients experiencing initial vancomycin 
serum trough concentrations of ≥15 mg/L have been shown to have a higher incidence of 
nephrotoxicity, and these patients may be at higher AKI risk [6-10]. Vancomycin serum trough 
concentrations ≥14 mg/L and therapy durations ≥ 7 days have been shown to be independent 
predictors of vancomycin-associated AKI in hospitalized adults [8]. Duration of vancomycin 
exposure was similar in our non-AKI and AKI patients. Hidayat et al [7] demonstrated 
 No AKI (n = 692) AKI (n = 167) Value 
Patient Characteristics     
Malea Ageb Weightb Initial SCr (mg/dL)b  384 (55.5) 3(1–9) 14.2 (8.7–
28.3) 0.4 (0.3–0.58)  
81 (48.5) 2 (1–9) 12.3 (7.3–
29) 0.3 (0.2–0.42)  
.104 .684 
.774 <.05  
Vancomycin Information     
Empiric vancomycin dose (mg/kg per day)  41.7 ± 15.6  43.1 ± 15.7  .294  
Empiric vancomycin dose >60 mg/kg per day Vancomycin 
duration (days)b  
166 (24) 5(4–8.8)  51 (30.5) 6 (4–9)  .08 .149  
Trough concentration obtained Initial vancomycin serum trough 
concentration (mg/L)b  
439 (63.4) 7.7 (5.8–11.2)  112 (67.1) 9.4 (6.3–13.5)  .380 <.05  
Initial vancomycin serum trough concentration  ≥15 mg/L  42 (9.6)  21 (18.8)  <.05  
Nephrotoxic Factorsa     
ICU admission  282 (40.8)  96 (57.5)  <.05  
Oncologic diagnosis  221 (31.9)  49 (29.3)  .517  
Dehydration  50 (7.2)  16 (9.6)  .305  
ECMO  47 (6.8)  13 (7.8)  .652  
Sepsis  111 (16)  33 (19.8)  .248  
Nephrotoxic Medicationsa     
Any concomitant nephrotoxic medication  460 (66.5)  117 (70.1)  .376  
Acyclovir (IV)  87 (12.6)  24 (14.4)  .534  
Amphotericin  33 (4.8)  12 (7.2)  .208  
Aminoglycoside  253 (36.6)  74 (44.3)  .064  
Calcineurin inhibitor  66 (9.5)  19 (11.4)  .475  
Contrast dye  313 (45.2)  87 (52.1)  .11  
Meropenem  92 (13.3)  35 (21)  <.05  
NSAID  188 (27.2)  44 (26.3)  .83  
Abbreviations: AKI, acute kidney injury; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IV, intravenous; NSAID, nonsteroidal 
anti-inflammatory drug; SCr, serum creatinine concentrations. 
aData reported as n (%). 
bData reported as median (interquartile range). 
Table 1 Characteristics of Patients With and Without AKI 
significantly higher vancomycin associated nephrotoxicity incidence in adults with MRSA 
infections when those patients had serum trough concentrations of 15–20 mg/L and were 
receiving concomitant nephrotoxic medications. A 2011 prospective study revealed that adults 
with MRSA infections have a greater risk of AKI with vancomycin serum trough concentrations 
of ≥15 mg/L (OR, 3.6; 95% CI, 1.75–7.59) [9]. Likewise, adults with MRSA pneumonia have 
been shown to be at a 3–5 times greater risk for developing AKI with vancomycin serum trough 
concentrations of ≥15 mg/L [6, 10]. 
 
Overall, we found a 19% (167 of 859) AKI incidence in children receiving at least 72 hours of 
vancomycin therapy, with no difference in incidence after increasing the empiric vancomycin 
dosing strategy in children at our institution. The empiric vancomycin dose was statistically 
similar in patients with and without AKI, although the median initial vancomycin trough was 
significantly higher in the AKI group. The reason for this discrepancy is unclear, but it could be 
related to an unobserved, underlying renal insufficiency before vancomycin initiation. It could 
also be that the AKI patients were sicker, compared to non-AKI patients, due to factors that were 
not considered in this study. 
 
Our findings are similar to the 14% (24 of 167) vancomycin-associated nephrotoxicity incidence 
in children shown by McKamy et al [11], who evaluated 167 patients. In that retrospective study, 
28% of children with a high vancomycin serum trough concentration (≥15 mg/L) were 
determined to have nephrotoxicity compared to 7% of children with a low trough concentration 
(<15 mg/L). Likewise, AKI incidence was increased in our study in children with an initial 
vancomycin trough concentration ≥15 mg/L. Similar to adults, empiric vancomycin doses in 
children necessary to attain higher trough concentrations are associated with AKI. 
 
McKamy et al [11] averaged serum trough concentrations obtained through the course of therapy 
to categorize patients into the high vs low trough group. We evaluated only the initial 
vancomycin serum trough concentration, and we found that a concentration of ≥15 mg/L and 
ICU admission were predictors for AKI within the first 7 days of therapy. Others have evaluated 
average vancomycin trough concentrations and the association with AKI throughout the 
vancomycin course, but they have not specifically assessed the relationship between initial 
vancomycin concentrations and early AKI development. Our finding that children with an initial 
vancomycin trough concentration of ≥15 mg/L are twice as likely to develop early AKI (within 
the first 7 days of therapy) is concerning. Despite the perceived increase in our institution’s 
empiric vancomycin dosing, the actual difference from 2007 to 2010 was not clinically 
significant, and there was no difference in the percentage of non-AKI and AKI patients receiving 
an empiric dose of >60 mg/kg per day. These findings raise the question of underlying kidney 
injury (not considered in this study), which is intensified with vancomycin and leads to elevated 
trough serum concentrations. The clinical impact of this identified association is unclear. 
LikeMcKamy et al [11] and many adult investigators, we used serum creatinine to categorize 
patients with AKI [6-9]. The pRIFLE criteria define AKI as a decrease in estimated creatinine 
clearance by at least 50%, which corresponds to an increase in serum creatinine by ≥ 50%, and 
that was modified to determine AKI in our study sample [12]. The importance of the early serum 
creatinine changes, as they relate to vancomycin dosing, could be questioned, particularly if AKI 
was so mild that it was not detected in a clinical setting and thus was not coded. Likewise, the 
increase in mortality we observed in association with AKI and in association with higher initial 
vancomycin trough concentrations in this cohort suggests that these early changes in creatinine 
may be of more clinical importance than appreciated, but it may also simply reflect that those 
children were more severely ill than those without AKI. The answers to these questions are 
beyond the scope of this retrospective study. 
 
Chart documentation can limit available information in retrospective studies. However, our study 
did include a large number of children. Despite the limited control the study provided for 
vancomycin dosing and monitoring, vancomycin concentrations were obtained in more than 60% 
of children exposed to vancomycin in our sample (551 of 859), which allows for a representative 
evaluation of any association with AKI. Although elevated serum creatinine was used as an 
exclusion criterion to avoid attributing AKI to vancomycin in patients with prior renal injury, 
serum creatinine elevation may lag behind a decrease in function. Therefore, some of the 
elevated vancomycin trough concentrations may have been due to undetected poor baseline renal 
function. In addition, the pRIFLE criteria provide little guidance for addressing serum creatinine 
fluctuations that are thought to be normal variation or due to testing variability (ie, change from 
0.1 to 0.2 mg/dL). This type of fluctuation occurred in approximately 18% of AKI patients in our 
sample, and it illustrates a limitation in using pRIFLE criteria alone as the sole AKI determinant. 
We only evaluated early AKI relative to initial vancomycin concentrations, and thus we cannot 
address whether ongoing exposure to higher vancomycin serum trough concentrations further 
increases AKI risk. 
 
CONCLUSIONS 
In our pediatric population, we found an initial vancomycin serum trough concentration of ≥15 
mg/L and ICU admission to be independent predictors for early AKI development. Higher 
vancomycin serum trough concentrations may be associated with AKI as determined by elevated 
SCr. Additional studies are needed to determine the longer-term clinical impact of high initial 
vancomycin trough concentrations. However, these findings indicate that closer therapeutic drug 
monitoring and renal function monitoring are clearly warranted for children who receive 
vancomycin therapy that extends beyond 72 hours and those with initial vancomycin trough 
concentrations of ≥15 mg/L. 
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